Olink is perhaps best known for its proximity extension assay (PEA) technology, which allows for highly sensitive, highly multiplexed protein measurements.
The New York Times Magazine writes that proteomics might be better poised than genomics to say when someone is falling ill.
The study lends support to the case for dried blood spots as a proteomics sample source for applications like biobanking and longitudinal patient monitoring.
Some six months after establishing itself as an independent entity, the company plans to roughly double its protein biomarker libraries by the end of the year.
The company said its new Massachusetts office will focus on driving US sales of its Proseek Multiplex platform for targeted human protein biomarker discovery.
The new company, Olink Proteomics, will focus on the Proseek Platform for protein detection, while the remaining firm will look to commercialize other parts of its IP portfolio.
Olink Proteomics will focus on developing protein biomarker discovery products while Olink Bioscience will work on other technologies arising from its IP portfolio.
Based on Olink's proximity ligation technology, Duolink allows for detection of low-abundance proteins with higher specificity than conventional immunoassays.
Eliminating enzymes makes for a less expensive and more accessible assay that could prove useful for purposes like infectious disease testing in developing countries.
Olink Bioscience has launched its new Proseek Multiplex Inflammation protein biomarker panel.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.